Why did BD lower its organic revenue growth guidance while raising EPS guidance?

BD cut its fiscal 2024 organic (FXN) revenue growth guidance to 5.0%–5.25% from 5.5%–6.25%, reflecting market dynamics such as China volume-based procurement, customer inventory de-stocking in anticoagulants and vaccines, and transitory softness in Biosciences instrument demand. The EPS raise of 5 cents at the midpoint reflects stronger margin execution and an improved full-year margin outlook under the BD Excellence operating system.

How much of the reported revenue beat was from one-time items?

Adjusted revenue of $5.06B exceeded reported revenue of $4.99B by $67M. That amount reflects accruals recognized from recent developments in Italian government medical device payback legislation and another legal matter, substantially relating to prior fiscal years. BD excludes these from adjusted revenue, so underlying growth is better represented by the 3.7% adjusted and 5.2% organic figures, though the reported 2.3% figure is the GAAP-basis comparison.

What is the financial impact of the pending Edwards Lifesciences Critical Care acquisition?

The filing discloses a definitive agreement to acquire Edwards' Critical Care Product Group for $4.2 billion. Transaction and financing costs of about $10 million and a net financing benefit of about $2 million were excluded from Q3 adjusted EPS. Long-term debt already rose to $18.1B at June 30, 2024 from $14.7B at September 30, 2023, so the deal will likely increase leverage, though the filing does not provide pro forma financing details.

What is the SEC matter, and what could it cost BD?

BD recorded a $50M charge in Other operating expense to accrue an estimated liability for an SEC investigation into certain reporting issues involving BD Alaris infusion pumps included in SEC disclosures before 2021. The company says it cannot predict the timing, scope, or outcome of the investigation, and that the ultimate liability could significantly exceed the amount accrued. The matter is separate from the Alaris remediation and U.S. return-to-market timing, which the filing also flags as a forward-looking risk.

Is BD's cash generation sustainable, and how did it change?

Nine-month operating cash flow from continuing operations rose to $2.67B from $1.67B, while capital expenditures fell to $429M from $580M, lifting free cash flow to $2.24B from $1.09B. Part of the improvement reflects a smaller working capital drag, with the change in operating assets and liabilities at -$340M versus -$1,413M a year earlier. Investors should note that the year-over-year comparison benefits from that lower working capital outflow, which may not repeat at the same magnitude.

BDX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.

BD reported fiscal Q3 2024 (quarter ended June 30, 2024) results with reported revenue of $4.99 billion^a, up 2.3% (2.9% foreign-currency neutral), and adjusted revenue of $5.06 billion, up 3.7% (4.3% FXN).

Adjusted revenue excludes $67 million^b of accruals tied to Italian medical device payback legislation and another legal matter, which mostly relate to prior fiscal years. Organic revenue growth was 5.2% on a foreign-currency-neutral basis. GAAP diluted EPS rose 23.5% to $1.68 and adjusted diluted EPS rose 18.2% to $3.50.

GAAP net income was $487 million^c versus $407 million a year earlier, helped by a much lower income tax provision ($13 million versus $64 million). Growth was led by BD Medical (+5.1% reported), with strong Medication Management Solutions (Alaris infusion) and Biologics and GLP-1 results, and BD Interventional (+1.8%) benefiting from double-digit growth in Surgery and PureWick. BD Life Sciences grew 2.7%, with Integrated Diagnostic Solutions up 4.5% and Biosciences down 1.4%.

Year-to-date cash generation was a standout. Net cash from continuing operating activities was $2.67 billion^d, up 60%, and free cash flow was $2.24 billion, up 106%. BD raised its fiscal 2024 adjusted diluted EPS guidance by 5 cents at the midpoint to $13.05–$13.15, citing margin performance.

However, it trimmed its organic revenue growth guidance to 5.0%–5.25% from 5.5%–6.25%, and GAAP revenue growth guidance is now about 3.7%. The filing also discloses a definitive agreement to acquire Edwards Lifesciences' Critical Care Product Group for $4.2 billion, and a $50 million accrual for an SEC investigation related to Alaris pump reporting issues, with the company noting the final liability could significantly exceed the accrued amount. For investors, the key tension is between strong margin execution and cash flow on one side and softer top-line guidance on the other.

Management attributes the lower revenue outlook to market dynamics, including China volume-based procurement, customer inventory de-stocking, and transitory softness in BD Biosciences instrument demand. Investors will want to watch the pace of the Alaris return to the U.S. market, the outcome of the SEC matter, and how the pending Edwards acquisition is financed and integrated, given that long-term debt rose to $18.1 billion from $14.7 billion at fiscal year-end 2023.

02—Key points

Key Highlights

Q3 FY2024 reported revenue of $4.99B (+2.3%); adjusted revenue of $5.06B (+3.7%) excluding $67M of prior-year-related Italian payback and legal accruals; organic growth of 5.2%
GAAP diluted EPS of $1.68 (+23.5%) and adjusted diluted EPS of $3.50 (+18.2%); GAAP net income rose to $487M from $407M, aided by a lower tax provision of $13M versus $64M
Fiscal 2024 adjusted diluted EPS guidance raised by $0.05 at the midpoint to $13.05–$13.15 (+6.9% to +7.7%), while organic revenue growth guidance was lowered to 5.0%–5.25% from 5.5%–6.25%
Year-to-date operating cash flow up 60% to $2.67B and free cash flow up 106% to $2.24B, with $500M in share repurchases during the nine months
Agreed to acquire Edwards Lifesciences' Critical Care Product Group for $4.2B, expanding BD's smart connected care and monitoring portfolio
BD Medical grew 5.1% (MMS +15.9% in the U.S., driven by Alaris infusion), while BD Interventional grew 1.8% with double-digit growth in Surgery and Peripheral Vascular Disease, offset by China-related Oncology declines
Recorded a $50M accrual for an SEC investigation tied to reporting on BD Alaris infusion pumps, with management noting the ultimate liability could significantly exceed the accrued amount

03—Questions

Frequently Asked Questions

Why did BD lower its organic revenue growth guidance while raising EPS guidance?
BD cut its fiscal 2024 organic (FXN) revenue growth guidance to 5.0%–5.25% from 5.5%–6.25%, reflecting market dynamics such as China volume-based procurement, customer inventory de-stocking in anticoagulants and vaccines, and transitory softness in Biosciences instrument demand. The EPS raise of 5 cents at the midpoint reflects stronger margin execution and an improved full-year margin outlook under the BD Excellence operating system.
How much of the reported revenue beat was from one-time items?
Adjusted revenue of $5.06B exceeded reported revenue of $4.99B by $67M. That amount reflects accruals recognized from recent developments in Italian government medical device payback legislation and another legal matter, substantially relating to prior fiscal years. BD excludes these from adjusted revenue, so underlying growth is better represented by the 3.7% adjusted and 5.2% organic figures, though the reported 2.3% figure is the GAAP-basis comparison.
What is the financial impact of the pending Edwards Lifesciences Critical Care acquisition?
The filing discloses a definitive agreement to acquire Edwards' Critical Care Product Group for $4.2 billion. Transaction and financing costs of about $10 million and a net financing benefit of about $2 million were excluded from Q3 adjusted EPS. Long-term debt already rose to $18.1B at June 30, 2024 from $14.7B at September 30, 2023, so the deal will likely increase leverage, though the filing does not provide pro forma financing details.
What is the SEC matter, and what could it cost BD?
BD recorded a $50M charge in Other operating expense to accrue an estimated liability for an SEC investigation into certain reporting issues involving BD Alaris infusion pumps included in SEC disclosures before 2021. The company says it cannot predict the timing, scope, or outcome of the investigation, and that the ultimate liability could significantly exceed the amount accrued. The matter is separate from the Alaris remediation and U.S. return-to-market timing, which the filing also flags as a forward-looking risk.
Is BD's cash generation sustainable, and how did it change?
Nine-month operating cash flow from continuing operations rose to $2.67B from $1.67B, while capital expenditures fell to $429M from $580M, lifting free cash flow to $2.24B from $1.09B. Part of the improvement reflects a smaller working capital drag, with the change in operating assets and liabilities at -$340M versus -$1,413M a year earlier. Investors should note that the year-over-year comparison benefits from that lower working capital outflow, which may not repeat at the same magnitude.

04—Continue

← View all 8-K filings